BRIEF published on 10/14/2025 at 22:05, 1 month 21 days ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 1 month 21 days ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 1 month 28 days ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 1 month 28 days ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 2 months 3 days ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 2 months 3 days ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
BRIEF published on 09/24/2025 at 22:05, 2 months 10 days ago Inventiva organizes an event for analysts and investors Event Phase 3 Inventiva MASH Lanifibranor
PRESS RELEASE published on 09/24/2025 at 22:00, 2 months 10 days ago Inventiva to Host Analyst and Investor Event on October 8, 2025 Inventiva to host analyst and investor event on October 8, 2025 featuring updates on lanifibranor and key MASH trends. Renowned experts to share insights on MASH landscape Inventiva Lanifibranor Analyst Event MASH Trends Expert Insights
BRIEF published on 08/25/2025 at 10:02, 3 months 10 days ago JP Morgan crosses threshold at Inventiva Voting Rights Actions Threshold Crossing JP Morgan Inventiva
BRIEF published on 08/25/2025 at 10:01, 3 months 10 days ago Threshold crossing for Inventiva Actions AMF Threshold Crossing Inventiva Great Point Partners
Published on 12/05/2025 at 02:35, 4 hours 29 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 4 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 59 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 4 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 33 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 13 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 38 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 48 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 53 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 13 hours 4 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 19 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 19 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
